bioAffinity Technologies (BIAF) EBIT (2021 - 2026)

bioAffinity Technologies has disclosed EBIT across 6 years of filings, most recently posting -$3.6 million for Q1 2026.

• In Q1 2026, EBIT fell 37.68% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$11.6 million (down 20.0% YoY), while the FY2025 annual figure was -$10.6 million, down 18.08% from the prior year.
• EBIT slipped to -$3.6 million in Q1 2026, from -$3.1 million in the prior quarter.
• Over the last five years, EBIT for BIAF reached as high as -$684119.0 in Q2 2022 and fell as low as -$3.6 million in Q1 2026.
• The 5-year median for EBIT is -$2.1 million (2024), against an average of -$2.1 million.
• Annual changes were most pronounced in 2023 — EBIT plunged 159.95% — and 2024, when it gained 13.97%.
• A 5-year view of EBIT shows it stood at -$1.6 million in 2022, then plunged by 44.26% to -$2.3 million in 2023, then retreated by 25.79% to -$2.9 million in 2024, then decreased by 6.46% to -$3.1 million in 2025, then declined by 15.3% to -$3.6 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$3.6 million, -$3.1 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.